Direct Costs of Hip Fractures in Patients Over 60 Years of Age in Belgium

Reginster, Jean‐Yves; Gillet, Pierre; Sedrine, Wafa Ben; Brands, G; Ethgen, Olivier; Froidmont, C de; Gosset, Christiane

doi:10.2165/00019053-199915050-00008

Cited by 74 publications

(36 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several studies have compared medical expenses before and after a hip fracture (Brainsky et al 1997, Zethraeus et al 1997, De Laet et al 1999, Reginster et al 1999) and have found increases in costs of USD 10,000-20,000 during the first year after the fracture.…”

Section: Discussionmentioning

confidence: 99%

Costs of internal fixation and arthroplasty for displaced femoral neck fractures

Rogmark

Carlsson

Johnell

et al. 2003

Acta Orthopaedica Scandinavica

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Costs of internal fixation and arthroplasty for displaced femoral neck fractures

Rogmark

Carlsson

Johnell

et al. 2003

Acta Orthopaedica Scandinavica

View full text Add to dashboard Cite

“…Hip, yearly long-term costs [22] 1102 ( CV, first 6 months [24,25] 2592 Wrist, first 6 months [26] 2302…”

Section: Model Structurementioning

confidence: 99%

Cost Effectiveness of Denosumab Compared with Oral Bisphosphonates in the Treatment of Post-Menopausal Osteoporotic Women in Belgium

Hiligsmann

Reginster

2011

PharmacoEconomics

Self Cite

View full text Add to dashboard Cite

Background: Denosumab has recently been shown to be well tolerated, to increase bone mineral density (BMD) and to significantly reduce the risk of hip, vertebral and non-vertebral fractures in the FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis every 6 Months) trial. It is becoming increasingly important to evaluate not only the therapeutic value of a new drug but also the cost effectiveness compared with the most relevant treatment alternatives. Objective: The objective of this study was to estimate the cost effectiveness of denosumab compared with oral bisphosphonates (branded and generic drugs) in the treatment of post-menopausal osteoporotic women in Belgium. Methods: Cost effectiveness of 3 years of treatment with denosumab was compared with branded risedronate and branded and generic alendronate using an updated version of a previously validated Markov microsimulation model. The model was populated with relevant cost, adherence and epidemiological data for Belgium from a payer perspective and the results were presented as costs per QALY gained (h, year 2009 values). Analyses were performed in populations (aged ‡60 years) in which osteoporosis medications are currently reimbursed in many European countries, i.e. those with BMD T-score of -2.5 or less or prevalent vertebral fracture. Patients receiving denosumab were assumed to have a 46% lower risk of discontinuation than those receiving oral bisphosphonates, and the effect of denosumab after treatment cessation was assumed to decline linearly to zero over a maximum of 1 year. Results: Denosumab was cost effective compared with all other therapies, assuming a willingness to pay of h40 000 per QALY gained. In particular, denosumab was found to be cost effective compared with branded alendronate and risedronate at a threshold value of h30 000 per QALY and denosumab was dominant (i.e. lower cost and greater effectiveness) compared with risedronate from the age of 70 years in women with a T-score of -2.5 or less and no prior fractures. The cost effectiveness of denosumab compared

show abstract

“…Previous studies have estimated reduction in costs and/or quality of life related to osteoporotic fractures (Liljegren et al 1997, Zethraeus et al 1997, Dolan and Torgerson 1998, Zethraeus and Gerdtham 1998, Reginster et al 1999, Haentjens et al 2001, Koeck et al 2001, Wiktorowicz et al 2001, Gabriel et al 2002, Wong et al 2002, Nurmi et al 2003, Lippuner et al 2005), but only a few of them are appropriate for use in economic evaluations and only one of them investigated the longterm consequences of fragility fractures (De Laet et al 1999). Not surprisingly, it is the hip frac-ture-the type of fracture associated with the highest mortality and most severe morbidity-that has been investigated most frequently in these studies.…”

mentioning

confidence: 99%

Long-term cost and effect on quality of life of osteoporosis-related fractures in Sweden

Ström¹,

Borgström

Zethraeus

et al. 2008

Acta Orthopaedica

View full text Add to dashboard Cite

Background and purpose Few economic or qualityof-life studies have investigated the long-term consequences of fragility fractures. This prospective observational data collection study assessed the cost and quality of life related to hip, vertebral, and wrist fracture 13-18 months after the fracture, based on 684 patients surviving 18 months after fracture.Patients and methods Data regarding resource use and quality of life related to fractures was collected using questionnaires at 7 research centers in Sweden. Information was collected using patient records, register sources, and by asking the patient. Quality of life was estimated using the EQ-5D questionnaire. Direct and indirect costs were estimated from a societal standpoint.Results The mean fracture-related cost 13-18 months after a hip, vertebral, or wrist fracture were estimated to be €2,422, €3,628, and €316, respectively. Between 12 and 18 months after hip, vertebral, and wrist fracture, utility increased by 0.03, 0.05, and 0.02, respectively. Compared to prefracture levels, the mean loss in quality of life between 13 and 18 months after fracture was estimated to be 0.05, 0.11, and 0.005 for hip, vertebral, and wrist fracture.Interpretation The sample of vertebral fracture patients was fairly small and included a high proportion of fractures leading to hospitalization, but the results indicate higher long-term costs and greater loss in quality of life related to vertebral fracture than previously believed.

show abstract

Direct Costs of Hip Fractures in Patients Over 60 Years of Age in Belgium

Abstract: With a total cost (acute hospital and outpatient costs) of BeF4,667,894,950 ($US126,159,323) per year in Belgium, proximal femoral neck fracture should be considered a major health economic problem and appropriate measures to prevent this disease should be rapidly undertaken.

Cited by 74 publications

References 15 publications

Costs of internal fixation and arthroplasty for displaced femoral neck fractures

Costs of internal fixation and arthroplasty for displaced femoral neck fractures

Cost Effectiveness of Denosumab Compared with Oral Bisphosphonates in the Treatment of Post-Menopausal Osteoporotic Women in Belgium

Long-term cost and effect on quality of life of osteoporosis-related fractures in Sweden

Contact Info

Product

Resources

About